StreetInsider.com News Articles

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Wed, 22 Jul 2026 08:40:00 -0400

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform

Watch the “What This Means” video here

TAMPA, Fla. and LONDON, July 22, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today that announced that its CEO, Abizer Gaslightwala, participated in a Virtual Investor "What This Means" interview focused on the Company's recently announced strategic research collaboration with Whitehawk

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Wed, 22 Jul 2026 08:40:00 -0400

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform

Watch the “What This Means” video here

Akari Therapeutics enters ADC research deal with Whitehawk Therapeutics

Tue, 21 Jul 2026 07:05:50 -0400

Akari Therapeutics, Plc (NASDAQ: AKTX) announced a research collaboration with Whitehawk Therapeutics to conduct preclinical studies combining Akari's PH1 spliceosome-modulating payload technology with Whitehawk's topoisomerase I inhibitor (TOP1i) antibody drug conjugate (ADC) platform.

Under the agreement, Akari will lead the design, execution, and evaluation of research activities. The initial collaboration will include multiple preclinical workstreams aimed at assessing dual payload compatibility and generating data to guide future development decisions.

The collaboration is expected to begin immediately, with interim data updates anticipated as studies progress. Both companies will jointly review resulting data to determine whether findings support broader development discussions.

Abizer Gaslightwala, President and

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Tue, 21 Jul 2026 07:05:00 -0400

Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities

TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Tue, 21 Jul 2026 07:05:00 -0400

Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities

Maxim Group Upgrades Akari Therapeutics (AKTX) to Buy

Mon, 20 Jul 2026 07:34:17 -0400

Maxim Group analyst Jason McCarthy upgraded Akari Therapeutics (NASDAQ: AKTX) from Hold to Buy with a price target of $30.00.

For an analyst ratings summary and ratings history on Akari Therapeutics click here. For more ratings news on Akari Therapeutics click here.

Shares of Akari Therapeutics closed at $11.01 yesterday.

Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board

Tue, 07 Jul 2026 08:55:14 -0400

Akari Therapeutics, Plc (NASDAQ: AKTX) announced the appointment of Patricia LoRusso, D.O., to its Scientific Advisory Board, according to a company press release dated July 7, 2026.

Dr. LoRusso currently serves as the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, where she also holds the roles of Chief of Experimental Therapeutics and Associate Cancer Center Director of Experimental Therapeutics. She previously held leadership positions at Wayne State University's Barbara Karmanos Cancer Institute, including Director of the Phase I Clinical Trials Program.

She is a past president of the American Association for Cancer Research (AACR) and has served as

Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board

Tue, 07 Jul 2026 08:55:14 -0400

Akari Therapeutics, Plc (NASDAQ: AKTX) announced the appointment of Patricia LoRusso, D.O., to its Scientific Advisory Board, according to a company press release dated July 7, 2026.

She is a past president of the American Association for Cancer Research (AACR) and has served as

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Tue, 07 Jul 2026 08:55:00 -0400

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics

Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial

TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board.

“Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Tue, 07 Jul 2026 08:55:00 -0400

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics

Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial

“Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment

Akari Therapeutics closes $5.5M PIPE, raises $8.3M total in Q2 2026

Mon, 29 Jun 2026 08:45:49 -0400

Akari Therapeutics, Plc (NASDAQ: AKTX) announced the completion of its previously announced private investment in public equity (PIPE) offering, consolidating the remaining scheduled investment closings into a single funding event on June 26, 2026.

The $5.5 million PIPE, led by existing investors, was originally structured in three tranches. The first closing occurred in late May 2026, while the second and third closings were consolidated into one final closing. Combined with approximately $2.8 million received from warrant exercises by some participating investors in May 2026, the company received approximately $8.3 million in total capital during the second quarter of 2026.

Under the securities

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Mon, 29 Jun 2026 08:45:00 -0400

Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points

TAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its previously announced PIPE through the consolidation of the remaining scheduled investment closings into a single funding event. Combined with warrant exercises completed

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Mon, 29 Jun 2026 08:45:00 -0400

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

Thu, 04 Jun 2026 09:30:00 -0400

Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential

Access the Akari CEO Corner here

TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing key themes emerging from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and Akari’s positioning within the evolving

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026

Thu, 04 Jun 2026 09:30:00 -0400

Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential

Access the Akari CEO Corner here

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Thu, 28 May 2026 09:17:00 -0400

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers

Watch the “What This Means” video here

TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor “What This Means” interview focused on the Company’s recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Thu, 28 May 2026 09:17:00 -0400

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers

Watch the “What This Means” video here

Akari Therapeutics reports preclinical data on cancer drug combination

Thu, 21 May 2026 17:01:20 -0400

Akari Therapeutics Plc (NASDAQ: AKTX) announced preclinical data showing synergistic activity between its experimental cancer drug AKTX-101 and KRAS inhibition in pancreatic cancer models with KRAS mutations.

The data, featured in an abstract for the American Society of Clinical Oncology Annual Meeting 2026, evaluated AKTX-101 in combination with adagrasib, a KRAS inhibitor, across pancreatic cancer cell lines harboring KRAS G12D and KRAS G12C mutations. The combination demonstrated synergistic cell killing in these KRAS mutant cell lines.

According to the company's statement, this synergistic inhibition was not observed with comparator topoisomerase I-targeting TROP2 antibody drug conjugates, which instead exhibited antagonism when paired with

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Thu, 21 May 2026 17:01:00 -0400

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models

Data supports the broader applicability of targeting RNA splicing to attack difficult-to-treat KRAS-driven cancers

Findings featured in ASCO 2026 online abstract further differentiate AKTX-101 from TROP2 ADCs utilizing Topoisomerase I inhibitor payloads

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Thu, 21 May 2026 17:01:00 -0400

Findings featured in ASCO 2026 online abstract further differentiate AKTX-101 from TROP2 ADCs utilizing Topoisomerase I inhibitor payloads

Akari Therapeutics raises $5.5 million in private placement

Thu, 21 May 2026 08:30:17 -0400

Akari Therapeutics Plc (NASDAQ: AKTX) announced the pricing of a private placement financing expected to raise approximately $5.5 million in gross proceeds. The biotechnology company develops antibody drug conjugates with RNA splicing modulator payloads for oncology applications.

The company issued 1,470,588 American Depository Shares at $3.74 per share, along with Series H, I and J warrants. The warrants require shareholder approval and are exercisable for 1,470,588 ADSs each at $3.74 per share. Series H warrants have an 18-month term, while Series I and J warrants have 60-month terms.

Akari plans to use the net proceeds for working capital and general corporate purposes,

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Thu, 21 May 2026 08:30:00 -0400

TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial.

“This financing reflects deep conviction from our long-term strategic investors

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Thu, 21 May 2026 08:30:00 -0400

“This financing reflects deep conviction from our long-term strategic investors

Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:05:00 -0400

Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026

Register for the event here

TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20,

Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:05:00 -0400

Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026

Register for the event here